Merit Medical selloff after CFO departure overdone, says Canaccord. Canaccord analyst Jason Mills said the selloff in Merit Medical due to the departure of its CFO is overdone. The analyst said the departure was a surprise to the company as well as Wall Street, leading him to believe its was a personal decision as opposed to something untoward about the company’s financials. Mills reiterated his Buy rating and $60 price target on Merit Medical shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.